Psychedelic drugs are demonstrating unique anti-addiction properties in clinical studies, in a world where over 1 billion people have substance abuse issues.
Psychedelic drugs are demonstrating unique anti-addiction properties in clinical studies, in a world where over 1 billion people have substance abuse issues.
MindMed and Forian will collaborate on drug R&D via the real-world evidence (RWE) pathway to drug development.
Two billion treatable (but untreated) mental health disorders globally. Eight million preventable deaths per year. The medicines that can save these lives are still illegal.
Cybin files two new patent applications in support of its proprietary psychedelic compounds.
Patent protection is of critical importance to the emerging psychedelic drug industry. With two types of drug patents and much additional patentable IP, there is much for investors to learn.
Optimi Health announces it has filed a Final Shelf Prospectus.
Mydecine signs a 5-year research agreement with Johns Hopkins University, with an initial focus on smoking cessation.
MindMed announces joining a research consortium, the Patient-Reported Outcome Consortium, to assist in its mission to advance medical innovation.
Cybin announces the filing of a non-provisional patent application, the company's 14th patent application.
Field Trip Health Ltd., a leader in the development and delivery of psychedelic therapies, reported its fiscal first quarter 2022 results for the three months ended June 30, 2021.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now